Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice

Japanese Journal of Clinical Oncology

Volumn 41, Issue 11, 2011, Pages 1265-1270

  Tanigawa, Go ^a   Kawashima, Atsunari ^b   Yamaguchi, Seiji ^a   Nishimura, Kazuo ^c   Miyoshi, Susumu ^d   Kajikawa, Jiro ^e   Meguro, Norio ^f   Yosioka, Toshiaki ^g   Oka, Toshitsugu ^h   Hara, Tsuneo ⁱ   Takayama, Hitoshi ^b   Nonomura, Norio ^b  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d OSAKA ROSAI HOSPITAL   (Japan)

^e SAKAI MUNICIPAL HOSPITAL   (Japan)

^f TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^g SUMITOMO HOSPITAL   (Japan)

^h OSAKA NATIONAL HOSPITAL   (Japan)

ⁱ IKEDA MUNICIPAL HOSPITAL   (Japan)

Author keywords

Japanese; Prognostic factor; Relative dose intensity; Renal cell carcinoma; Sorafenib

Indexed keywords

INTERFERON; INTERLEUKIN 2; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BRAIN HEMORRHAGE; CANCER CONTROL; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEMATOCHEZIA; HOARSENESS; HUMAN; HYPERCALCEMIA; HYPERTENSION; JAPAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PANCREATITIS; PNEUMONIA; PROGNOSIS; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZENESULFONATES; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; PYRIDINES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80155136807     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr137     Document Type: Article

References (16)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Reuter VE, Presti JC, Jr. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 2000;27:124-37.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
4. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205.
7. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
8. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63.
9. Kawashima A, Takayama H, Arai Y, Tanigawa G, Nin M, Kajikawa J, et al. One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients. Eur J Cancer 2011;47:1521-6.
10. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37:755-62.
11. Zhang H, Dong B, Lu JJ, Yao X, Zhang S, Dai B, et al. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. BMC Cancer 2009;9:249.
12. Ueda T, Imamura Y, Komaru A, Fukasawa S, Sazuka T, Suyama T, et al. Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. Int J Urol 17:811-5.
13. Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 57:317-25.
14. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9.
15. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006;42:548-56.
16. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.